Jean Coutu profit rises 10 pct on generic drug business

Thu Jan 10, 2013 8:01am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(Reuters) - Canadian pharmacy chain Jean Coutu Group Inc (PJCa.TO: Quote) reported a 10 percent increase in third-quarter profit on Thursday, driven by strong sales at Pro Doc, its generic drug manufacturing subsidiary.

Sales at Pro Doc rose 12 percent to C$41.4 million ($41.9 million) for the fiscal third quarter, ended December 1, and the unit's contribution to the parent company's operating income before amortization rose to C$16.1 million from C$15.4 million a year earlier.

Prescription sales growth at Jean Coutu and rivals such as Shoppers Drug Mart Corp SC.TO has been held back in recent years by a crackdown by provincial governments on generic drug prices and reimbursement rules. But Jean Coutu has said Pro Doc may help boost margins over the long term.

Shoppers Drug Mart has a similar private-label generic drug unit, but it has been hindered by a regulation in Ontario, its biggest market, that forbids drugstores from selling their own private-label drugs. The bulk of Jean Coutu's network of 405 pharmacies is in Quebec, which has no such rule.

Canada's top court is set to hear a challenge to the Ontario law, brought by Shoppers Drug and closely-held competitor Katz Group, in May.

Increasing use of generic drugs has exacerbated the impact of generic-drug reforms. Jean Coutu said 61.8 percent of its third-quarter prescriptions were for generics, up from 57.2 percent a year earlier.

The company said sales at established stores, a key measure for retailers, increased 2.6 percent in the quarter, and rose 2.0 percent for non-pharmacy, or "front-end," goods.

Net profit for the quarter rose to C$56.2 million, or 26 Canadian cents a share, from C$51.2 million, or 23 Canadian cents, a year earlier.

Analysts, on average, had been expecting 26 Canadian cents a share, according to Thomson Reuters I/B/E/S.   Continued...